These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34046363)

  • 1. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
    Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
    Front Oncol; 2021; 11():678634. PubMed ID: 34046363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
    Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
    Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
    Becnel MR; Lee HC
    Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-automation of keratopathy visual acuity grading of corneal events in belantamab mafodotin clinical trials: clinical decision support software.
    Talekar MK; Painter JL; Elizalde MA; Thomas M; Stein HK
    Front Digit Health; 2023; 5():1138453. PubMed ID: 37881364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
    Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
    Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R; Degli Esposti S; Byrne J; Opalinska J; Baron J; Piontek T; Gupta I; Dana R; Farooq AV; Colby K; Jakubowiak A
    Blood Cancer J; 2021 May; 11(5):103. PubMed ID: 34039952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
    Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
    Cancer; 2024 Aug; 130(15):2629-2641. PubMed ID: 38630908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report.
    Marquant K; Quinquenel A; Arndt C; Denoyer A
    J Hematol Oncol; 2021 Oct; 14(1):159. PubMed ID: 34602074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
    Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
    Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
    Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
    Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
    J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
    Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Belantamab Mafodotin on Primary Myeloma-Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells.
    Matula Z; Uher F; Vályi-Nagy I; Mikala G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
    Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
    Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
    Richardson PG; Lee HC; Abdallah AO; Cohen AD; Kapoor P; Voorhees PM; Hoos A; Wang K; Baron J; Piontek T; Byrne J; Richmond S; Jewell RC; Opalinska J; Gupta I; Lonial S
    Blood Cancer J; 2020 Oct; 10(10):106. PubMed ID: 33097687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
    de la Rubia J; Alonso R; Clavero ME; Askari E; García A; Antón C; Fernández M; Escalante F; García A; Rios-Tamayo R; Conesa V; Bermúdez MA; Merchán B; Velasco AE; Blanchard MJ; Sampol A; Gainza E; Hernández PM; Alegre A
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belantamab mafodotin associated corneal microcyst-like epithelial changes.
    Chuang K; Pineda R; Liu S
    Am J Ophthalmol Case Rep; 2022 Mar; 25():101392. PubMed ID: 35198816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.
    Gallin V; Nölle B; Schub N; Roider J
    Cornea; 2024 Jun; ():. PubMed ID: 38900711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
    Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.